Evolus, Inc.
EOLSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeEvolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. Valued at $432.7M, EOLS is a small-cap name in its sector. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Market Cap
$432.7M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
24.64
EPS (TTM)
$-0.70
EPS (Fwd)
$0.27
ROE
—
ROA
-9.1%
Cash
$49.8M
Total Debt
$164.9M
Free CF
-$23.2M
52W Change
-28.5%
Annual Financials
Cash vs Debt
Evolus, Inc. carries $164.9M in total debt against $49.8M in cash reserves — debt is roughly 3.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$23.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $148.6M (2022) to $297.2M (2025), reflecting a 100% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Evolus, Inc.'s trajectory.